JP4478561B2 - 薬学的に活性なジスルフィド塩の合成方法 - Google Patents
薬学的に活性なジスルフィド塩の合成方法 Download PDFInfo
- Publication number
- JP4478561B2 JP4478561B2 JP2004501366A JP2004501366A JP4478561B2 JP 4478561 B2 JP4478561 B2 JP 4478561B2 JP 2004501366 A JP2004501366 A JP 2004501366A JP 2004501366 A JP2004501366 A JP 2004501366A JP 4478561 B2 JP4478561 B2 JP 4478561B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- dimesna
- synthesizing
- pharmaceutically active
- mesna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims description 33
- 230000002194 synthesizing effect Effects 0.000 title claims description 8
- 150000002019 disulfides Chemical class 0.000 title description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- -1 alkali metal salt Chemical class 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims 1
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 description 17
- 229950009278 dimesna Drugs 0.000 description 16
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 13
- 229960004635 mesna Drugs 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003223 protective agent Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- KBFJUSPXGQWLBO-UHFFFAOYSA-N sodium;2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound [Na].[Na].OS(=O)(=O)CCSSCCS(O)(=O)=O KBFJUSPXGQWLBO-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NLXJVFIECSBALS-UHFFFAOYSA-L disodium bromomethyl-dioxido-oxo-lambda5-phosphane Chemical compound BrCP([O-])([O-])=O.[Na+].[Na+] NLXJVFIECSBALS-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- UJIOMPDETDVHAO-UHFFFAOYSA-M sodium;2-acetylsulfanylethanesulfonate Chemical compound [Na+].CC(=O)SCCS([O-])(=O)=O UJIOMPDETDVHAO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
- C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
2,2’−ジチオビスエタンスルホン酸二ナトリウム(ジメスナ(Dimesna))ならびに2,2’−ジチオビスエタンスルホン酸の他の塩及び誘導体は、化学療法における保護剤として知られており、特定の型の癌を患う患者に与えられる白金錯体系抗腫瘍剤(platinum complex antitumor drug)の毒性を軽減するために使用される。白金の保護剤としてのジメスナなどの化合物は、米国特許第5,789,000号;同第5,866,169号;同第5,866,615号;同第5,866,617号;及びこの文献の他の箇所に開示されている。
本発明の方法は、一般的に入手可能な出発原料からジメスナ及びその誘導体を合成する2工程のシングルポット方法を包含する。
本明細書に記載される好ましい実施形態は、完全であることを意図するものではなく、開示された明確な形態に本発明を限定することを意図するものでもない。これらの好ましい実施形態は、本発明の原理ならびにその適用及び実用を説明することにより、当業者がその教示を理解できるように選択及び記載される。
S−アセチル−メチルメルカプトホスホン酸ジエチルの調製
ブロモメチルホスホン酸二ナトリウム(2.6g)の無水テトラヒドロフラン溶液に、固体のチオ酢酸カリウム(5.2g)を添加し、室温で15時間攪拌する。次いで、この有機部分をエーテル(200mL)中に回収し、そして水で洗浄する(100mL×3回)。次いで、この有機部分を無水硫酸ナトリウムで乾燥し、濾過し、そして濃縮乾固する。次いで、この生成物を、NMRによって分析する。
1H−NMR: 2.23(3H,s),2.72(2H,m),3.01(2H,m)。
S−アセチル−2−メルカプトエタンスルホン酸ナトリウムの調製
250mLの工程用水中の2−ブロモエタンスルホン酸一ナトリウム塩(25グラム)及びチオ酢酸カリウム(20.6グラム)を用いた。次いで、この反応混合物を加熱して、12時間還流する。次いで、この反応混合物を、減圧下、80℃で容量100mLまで濃縮し、生成物を、直接結晶化させる。次いで、生成物は、NMRにより特徴付けられる。
1H−NMR: 2.22(3H,s),2.7(2H,m),3.01(2H,m)。
2,2’−ジチオビス−エタンスルホン酸二ナトリウムの調製
現行のS−アセチル−2−メルカプトエタンスルホン酸ナトリウム塩(20g)を水に溶解し、1N水酸化ナトリウムを添加してpHを9.0に調整する。次いで、反応混合物を、酸素をバブリングしながら48時間攪拌する。次いで、この水性部分を濃縮し、濃縮物を直接結晶化させる。
1H−NMR:2.8−2.9(2H,m);3.1−3.2(2H,m)。
S−アセチル−2−メルカプトエタンスルホン酸ナトリウムの調製
ビニルスルホン酸一ナトリウム塩(25%水溶液、100mL)を、還流冷却器を備えたフラスコに入れ、チオ酢酸カリウム(20.6g)を添加する。次いで、この反応混合物を加熱して、96時間還流する。次いで、この反応混合物を、減圧下、80℃で容量50mLまで濃縮し、濃縮物を直接結晶化させる。次いで、この生成物は、NMRによって特徴付けられる。
1H−NMR:2.22(3H,s),2.7(2H,m),3.01(2H,m)。
Claims (8)
- Xが、ハロゲンであり、かつ硫化試薬が、チオ酢酸のアルカリ金属塩である請求項1記載の方法。
- Xが、CH2=CH−である請求項1記載の方法。
- 塩基が、強塩基である請求項1記載の方法。
- 強塩基が、水酸化ナトリウムである請求項4記載の方法。
- 酸素源が酸素ガスであり、前記酸素源が反応容器中にバブリングされる請求項1記載の方法。
- 水溶液中で行われる請求項1記載の方法。
- 式(I)の化合物が対称ジスルフィドである請求項1記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/135,756 US6504049B1 (en) | 2002-04-30 | 2002-04-30 | Process for synthesizing pharmaceutically active disulfide salts |
PCT/US2003/013178 WO2003093226A1 (en) | 2002-04-30 | 2003-04-29 | Process for synthesizing pharmaceutically active disulfide salts |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005523935A JP2005523935A (ja) | 2005-08-11 |
JP2005523935A5 JP2005523935A5 (ja) | 2006-06-22 |
JP4478561B2 true JP4478561B2 (ja) | 2010-06-09 |
Family
ID=22469512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501366A Expired - Lifetime JP4478561B2 (ja) | 2002-04-30 | 2003-04-29 | 薬学的に活性なジスルフィド塩の合成方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6504049B1 (ja) |
EP (1) | EP1499587B1 (ja) |
JP (1) | JP4478561B2 (ja) |
AU (1) | AU2003231169B2 (ja) |
CA (1) | CA2483775C (ja) |
DK (1) | DK1499587T3 (ja) |
ES (1) | ES2523653T3 (ja) |
MX (1) | MXPA04010859A (ja) |
PT (1) | PT1499587E (ja) |
WO (1) | WO2003093226A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2811987A1 (fr) * | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
US7317124B2 (en) | 2003-11-13 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates |
CN100450999C (zh) * | 2003-12-17 | 2009-01-14 | 比奥纽默里克药物公司 | 合成二硫化物的方法 |
US7282602B2 (en) * | 2004-09-21 | 2007-10-16 | Bionumerik Pharmaceuticals, Inc. | Medicinal disulfide salts |
US20070219268A1 (en) * | 2006-03-16 | 2007-09-20 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
JP5109081B2 (ja) * | 2006-04-26 | 2012-12-26 | 東洋紡株式会社 | アルケンスルホン酸塩を用いたチオカルボアルキルアルカンスルホン酸塩、メルカプトアルカンスルホン酸塩およびジチオビス(アルカンスルホン酸)塩の製造方法 |
AU2008326461B2 (en) * | 2007-11-20 | 2014-11-13 | Lankenau Institute For Medical Research | Disulfide chemotherapeutic agents and methods of use thereof |
AU2008352597B2 (en) | 2008-03-14 | 2012-03-08 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
CN102014891B (zh) | 2008-03-14 | 2013-12-18 | 比奥纽默里克药物公司 | 增加癌症患者存活时间的化合物的组合物和使用方法 |
WO2010132771A1 (en) | 2009-05-15 | 2010-11-18 | Lankenau Institute For Medical Research | Methods and kits for measuring toxicity and oxidative stress in live cells |
CN108914171B (zh) * | 2018-07-19 | 2020-05-19 | 广东工业大学 | 一种加速铜沉积添加剂及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2396879A (en) * | 1945-04-12 | 1946-03-19 | Eastman Kodak Co | Sulphur-containing esters |
CS252564B1 (cs) * | 1985-06-17 | 1987-09-17 | Jiri Jary | Způsob výroby 2-merkaptoethansulfonové kyseliny |
AU718575B2 (en) | 1996-10-01 | 2000-04-13 | Bionumerik Pharmaceuticals, Inc. | Process for producing diothiobis-alkanesulfonates and phosphonates |
FR2811987A1 (fr) * | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
-
2002
- 2002-04-30 US US10/135,756 patent/US6504049B1/en not_active Expired - Lifetime
-
2003
- 2003-04-29 DK DK03724301.1T patent/DK1499587T3/en active
- 2003-04-29 WO PCT/US2003/013178 patent/WO2003093226A1/en active Application Filing
- 2003-04-29 EP EP03724301.1A patent/EP1499587B1/en not_active Expired - Lifetime
- 2003-04-29 CA CA2483775A patent/CA2483775C/en not_active Expired - Fee Related
- 2003-04-29 JP JP2004501366A patent/JP4478561B2/ja not_active Expired - Lifetime
- 2003-04-29 PT PT37243011T patent/PT1499587E/pt unknown
- 2003-04-29 MX MXPA04010859A patent/MXPA04010859A/es active IP Right Grant
- 2003-04-29 ES ES03724301.1T patent/ES2523653T3/es not_active Expired - Lifetime
- 2003-04-29 AU AU2003231169A patent/AU2003231169B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2003231169B2 (en) | 2008-09-04 |
PT1499587E (pt) | 2014-11-21 |
EP1499587B1 (en) | 2014-11-05 |
MXPA04010859A (es) | 2005-02-14 |
WO2003093226A1 (en) | 2003-11-13 |
US6504049B1 (en) | 2003-01-07 |
CA2483775A1 (en) | 2003-11-13 |
EP1499587A4 (en) | 2006-05-24 |
CA2483775C (en) | 2011-02-08 |
ES2523653T3 (es) | 2014-11-28 |
DK1499587T3 (en) | 2015-01-26 |
JP2005523935A (ja) | 2005-08-11 |
EP1499587A1 (en) | 2005-01-26 |
AU2003231169A1 (en) | 2003-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4478561B2 (ja) | 薬学的に活性なジスルフィド塩の合成方法 | |
JP4104662B2 (ja) | メルカプトアルカンスルホネート及びホスホネート及びその誘導体の製造方法 | |
EP1109779B8 (en) | Novel mercaptans and disulfides | |
US7053240B2 (en) | Process for synthesizing disulfides | |
JP2005523935A5 (ja) | ||
JP5015781B2 (ja) | 医薬用ジスルフィド塩 | |
WO2015011206A1 (en) | Process for the preparation of a polyunsaturated ketone compound | |
EP1678129B1 (en) | Improved process for preparing benzhydrylthioacetamide | |
JPH04266890A (ja) | 金(i)メルカプチドの製造方法 | |
JPH0386890A (ja) | 有機ゲルマニウム化合物及びその製造方法 | |
FR2678623A1 (fr) | Nouveaux complexes du platine (ii) antitumoraux et procede pour leur preparation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060427 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090511 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091027 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100302 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100315 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4478561 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130319 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130319 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140319 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |